概括
干扰素-释放试验 (IGRA) 显示出良好的诊断准确性和成本效益,用于潜伏结核病感染 (LTBI) 查. 虽然公共资金可能会增加成本,但IGRA在特定的高风险群体中提供了显著的节省,并被医疗保健提供者所偏爱.
科学领域:
- 公共卫生和传染病诊断公共卫生和传染病诊断
- 卫生技术评估 卫生技术评估
- 医疗保健中的成本效益分析.
背景情况:
- 潜伏性结核病感染 (LTBI) 构成患有活跃结核病 (TB) 的风险.
- 查和治疗LTBI对于预防不良健康结果和社区传播至关重要.
- 干扰素-释放试验 (IGRA) 与用于检测LTBI的标准结核素皮肤试验 (TST) 相比进行评估.
研究的目的:
- 为了评估IGRA的诊断准确度与LTBI检测的TST相比.
- 评估公共资助IGRA测试的成本效益和预算影响.
- 了解医疗保健提供者对LTBI测试方法的偏好和价值观.
主要方法:
- 系统的文献搜索临床证据 (系统性审查的概述) 和经济证据 (加拿大成本效益研究).
- 开发一种概率决策树模型,以估计IGRA与TST的增量成本.
- 考虑高风险子群体,包括BCG接种疫苗的个人和患有并发症的人.
- 在安大略省公开资助IGRA的五年预算影响的估计.
- 通过对医疗保健提供者的调查收集定性数据.
主要成果:
- IGRA显示出良好的诊断准确性,特别是高特异性,作为LTBI的规则测试.
- IGRA的错误阳性结果比TST的错误阳性结果更少,特别是在免疫力低下的人群,儿童,老年人和BCG接种疫苗的人群中.
- 经济研究表明,在高风险人群中,IGRA与单独使用TST相比具有成本效益或节省成本.
- 在安大略省,公开资助IGRA预计将产生额外的成本 (5年内299万美元至1880万美元),但估计BCG疫苗接种移民和接触调查 (1630万美元+) 将节省成本.
- 医疗保健提供者更喜欢IGRA,因为它的方便性 (一次访问) 和感知到的患者偏好.
结论:
- 根据加拿大结核病标准,IGRA证明了LTBI查的良好的诊断准确性和成本效益.
- 在安大略省,IGRA的公共资金对预算产生了混合的影响,在特定群体中可能节省资金,而在其他群体中则增加成本.
- 医疗保健提供者偏好支持IGRA,特别是对于面临TST障碍的患者.
更多相关视频
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
2.1K
09:34An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
1.7K
相关概念视频
Pulmonary Tuberculosis IV
132
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
132
Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pulmonary Tuberculosis II
211
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Pulmonary Tuberculosis III
299
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
299
